[Skip to Navigation]
May 1989

Neuroleptic Responsiveness in Siblings Concordant for Schizophrenia

Author Affiliations

HSC, T-10 Department of Psychiatry SUNY at Stony Brook Stony Brook, NY 11704-8101 Deborah Dauphinais, MD Clinical Neurogenetics Branch National Institute of Mental Health Bethesda, Md

Arch Gen Psychiatry. 1989;46(5):477. doi:10.1001/archpsyc.1989.01810050091014

To the Editor.—  Recently we reported the results of a clinical examination of siblings who were concordant for schizophrenia.1 We have received queries from several interested colleagues as to whether, in addition to the clinical characteristics we noted, we also were able to detect whether pharmacologic response to antipsychotic medication was similar within families. The interest in this issue is twofold: (1) response to neuroleptics is known to have a strong genetic basis, and thus could be hypothesized to be related to the genetics of schizophrenia; and (2) faced with the potential heterogeneity of the cause of schizophrenia, division of subjects by pharmacologic responsiveness to define specific biologic entities could be a valid method of classification. Siblings concordant for schizophrenia could be examined to test these hypotheses based on the assumption that within each family schizophrenic illness will have the same cause, genetic vulnerability, and pathogenesis. Treatment response, however,

Add or change institution